17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Co‐culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Arteriovenous fistulas (AVFs) are the preferred vascular access for haemodialysis of patients suffering from end‐stage renal disease, a worldwide public health problem. However, they are prone to a high rate of failure due to neointimal hyperplasia and stenosis. This study aimed to determine if osteopontin (OPN) was induced in hypoxia and if OPN could be responsible for driving AVF failure. Identification of new factors that participate in remodelling of AVFs is a challenge. Three cell lines representing the cells of the three layers of the walls of arteries and veins, fibroblasts, smooth muscle cells and endothelial cells, were tested in mono‐ and co‐culture in vitro for OPN expression and secretion in normoxia compared to hypoxia after silencing the hypoxia‐inducible factors (HIF‐1α, HIF‐2α and HIF‐1/2α) with siRNA or after treatment with an inhibitor of NF‐kB. None of the cells in mono‐culture showed OPN induction in hypoxia, whereas cells in co‐culture secreted OPN in hypoxia. The changes in oxygenation that occur during AVF maturation up‐regulate secretion of OPN through cell‐cell interactions between the different cell layers that form AVF, and in turn, these promote endothelial cell proliferation and could participate in neointimal hyperplasia.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.

          Acidosis of the tumor microenvironment is typical of a malignant phenotype, particularly in hypoxic tumors. All cells express multiple isoforms of carbonic anhydrase (CA), enzymes catalyzing the reversible hydration of carbon dioxide into bicarbonate and protons. Tumor cells express membrane-bound CAIX and CAXII that are controlled via the hypoxia-inducible factor (HIF). Despite the recognition that tumor expression of HIF-1alpha and CAIX correlates with poor patient survival, the role of CAIX and CAXII in tumor growth is not fully resolved. To understand the advantage that tumor cells derive from expression of both CAIX and CAXII, we set up experiments to either force or invalidate the expression of these enzymes. In hypoxic LS174Tr tumor cells expressing either one or both CA isoforms, we show that (a) in response to a "CO(2) load," both CAs contribute to extracellular acidification and (b) both contribute to maintain a more alkaline resting intracellular pH (pH(i)), an action that preserves ATP levels and cell survival in a range of acidic outside pH (6.0-6.8) and low bicarbonate medium. In vivo experiments show that ca9 silencing alone leads to a 40% reduction in xenograft tumor volume with up-regulation of ca12 mRNA levels, whereas invalidation of both CAIX and CAXII gives an impressive 85% reduction. Thus, hypoxia-induced CAIX and CAXII are major tumor prosurvival pH(i)-regulating enzymes, and their combined targeting shows that they hold potential as anticancer targets.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Clinical practice guidelines for vascular access.

            (2006)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis.

              Advantages of the arteriovenous fistula (AVF), including long patency and few complications, were ascertained more than 2 decades ago and may not apply to the contemporary dialysis population. Systematic review and meta-analysis. Estimates were pooled using a random-effects model and sources of heterogeneity were explored using metaregression. Patients treated with long-term hemodialysis using an AVF. English-language studies indexed in MEDLINE between 2000 and 2012 using prospectively collected data on 100 or more AVFs. Age, AVF location, and study location. Outcomes of interest were primary AVF failure and primary and secondary patency at 1 and 2 years. 7,011 citations were screened and 46 articles met eligibility criteria (62 unique cohorts; n = 12,383). The rate of primary failure was 23% (95% CI, 18%-28%; 37 cohorts; 7,393 AVFs). When primary failures were included, the primary patency rate was 60% (95% CI, 56%-64%; 13 studies; 21 cohorts; 4,111 AVFs) at 1 year and 51% (95% CI, 44%-58%; 7 studies; 12 cohorts; 2,694 AVFs) at 2 years. The secondary patency rate was 71% (95% CI, 64%-78%; 10 studies; 11 cohorts; 3,558 AVFs) at 1 year and 64% (95% CI, 56%-73%; 6 studies; 11 cohorts; 1,939 AVFs) at 2 years. In metaregression, there was a significant decrease in primary patency rate in studies that started recruitment in more recent years. Low quality of studies, variable clinical settings, and variable definitions of primary AVF failure. In recent years, AVFs had a high rate of primary failure and low to moderate primary and secondary patency rates. Consideration of these outcomes is required when choosing a patient's preferred access type. Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                sadaghianloo.n@chu-nice.fr
                mazure@unice.fr
                Journal
                J Cell Mol Med
                J. Cell. Mol. Med
                10.1111/(ISSN)1582-4934
                JCMM
                Journal of Cellular and Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1582-1838
                1582-4934
                07 February 2020
                March 2020
                : 24
                : 5 ( doiID: 10.1111/jcmm.v24.5 )
                : 2931-2941
                Affiliations
                [ 1 ] Université Côte d’Azur Institute for Research on Cancer and Aging of Nice (IRCAN) CNRS‐UMR 7284‐Inserm U1081 Centre Antoine Lacassagne University of Nice Sophia‐Antipolis Nice France
                [ 2 ] Department of Vascular Surgery Centre Hospitalier Universitaire de Nice Nice France
                [ 3 ] Department of Emergency Medicine Centre Hospitalier Universitaire de Nice Nice France
                [ 4 ] Centre Scientifique de Monaco (CSM) Monaco Monaco
                [ 5 ] Faculty of Medicine LP2M CNRS‐UMR 7370 Nice France
                [ 6 ] Department of Surgery and the Vascular Biology and Therapeutics Program Yale University New Haven CT USA
                [ 7 ] Department of Vascular Surgery VA Connecticut Healthcare Systems West Haven CT USA
                [ 8 ]Present address: Centre de Méditerranéen de Médecine Moléculaire (C3M) INSERM U1065 Université Côte d’Azur Nice Cedex 03 France
                Author notes
                [*] [* ] Correspondence

                Nirvana Sadaghianloo and Nathalie M. Mazure, INSERM U1065, C3M, 151 Route de St Antoine de Ginestière, BP2 3194, 06204 Nice Cedex 03, France.

                Emails: sadaghianloo.n@ 123456chu-nice.fr ; mazure@ 123456unice.fr

                Author information
                https://orcid.org/0000-0003-1350-7161
                Article
                JCMM14905
                10.1111/jcmm.14905
                7077551
                32032472
                23761cf8-ec6b-46bb-83fd-6294fd115eaa
                © 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 31 July 2019
                : 20 November 2019
                : 23 November 2019
                Page count
                Figures: 4, Tables: 0, Pages: 11, Words: 7251
                Funding
                Funded by: Fondation Flavien
                Funded by: Société Française de Chirurgie Vasculaire et Endovasculaire
                Funded by: Fondation ARC pour la Recherche sur le Cancer , open-funder-registry 10.13039/501100004097;
                Funded by: Fondation de France , open-funder-registry 10.13039/501100004431;
                Funded by: La Ligue contre le Cancer
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                March 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.8 mode:remove_FC converted:17.03.2020

                Molecular medicine
                arteriovenous fistula,hypoxia,hypoxia‐inducible factor,metabolism,osteopontin
                Molecular medicine
                arteriovenous fistula, hypoxia, hypoxia‐inducible factor, metabolism, osteopontin

                Comments

                Comment on this article